- Home
- ADNT vs MYGN Comparison
ADNT vs MYGN Comparison
Compare ADNT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADNT
- MYGN
- Stock Information
- Founded
- ADNT 2016
- MYGN 1991
- Country
- ADNT Ireland
- MYGN United States
- Employees
- ADNT N/A
- MYGN N/A
- Industry
- ADNT Auto Parts:O.E.M.
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ADNT Consumer Discretionary
- MYGN Health Care
- Exchange
- ADNT Nasdaq
- MYGN Nasdaq
- Market Cap
- ADNT 1.5B
- MYGN 2.0B
- IPO Year
- ADNT N/A
- MYGN 1995
- Fundamental
- Price
- ADNT $16.85
- MYGN $13.67
- Analyst Decision
- ADNT Hold
- MYGN Hold
- Analyst Count
- ADNT 9
- MYGN 11
- Target Price
- ADNT $23.50
- MYGN $24.27
- AVG Volume (30 Days)
- ADNT 1.1M
- MYGN 1.1M
- Earning Date
- ADNT 02-05-2025
- MYGN 02-25-2025
- Dividend Yield
- ADNT N/A
- MYGN N/A
- EPS Growth
- ADNT N/A
- MYGN N/A
- EPS
- ADNT 0.20
- MYGN N/A
- Revenue
- ADNT $14,688,000,000.00
- MYGN $823,600,000.00
- Revenue This Year
- ADNT N/A
- MYGN $13.82
- Revenue Next Year
- ADNT $0.91
- MYGN $4.59
- P/E Ratio
- ADNT $84.30
- MYGN N/A
- Revenue Growth
- ADNT N/A
- MYGN 12.15
- 52 Week Low
- ADNT $16.28
- MYGN $12.87
- 52 Week High
- ADNT $36.04
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ADNT 33.06
- MYGN 35.58
- Support Level
- ADNT $16.82
- MYGN $13.39
- Resistance Level
- ADNT $17.67
- MYGN $13.95
- Average True Range (ATR)
- ADNT 0.69
- MYGN 0.55
- MACD
- ADNT -0.02
- MYGN 0.16
- Stochastic Oscillator
- ADNT 20.58
- MYGN 42.78
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.